Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Shares of Geron (NASDAQ:GERN) plunged 30% early Wednesday after the company released its Q4 earnings report. Geron reported a ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m ...

Geron Corp (GERN) reports a robust cash reserve and key FDA approval for Rytelo, but faces flat revenue trends and leadership changes in its commercial strategy.

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institute for ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase ...

Thanks for joining us today. 2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor. RYTELO has a unique mechanism of action that represents a highly ...

Geron (GERN), the biopharmaceutical company behind the approved telomerase inhibitor for specific lower-risk myelodysplastic syndromes, has experienced significant success with its product RYTELO.

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company's net product revenue for RYTELO reached $47.5 million in ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...